Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Vrdoljak · SciRah

Researcher profile · Semantic Scholar

E. Vrdoljak

Share profile

E. Vrdoljak — researcher profile on SciRah

h-index: 24
Works: 138
Citations: 3,598

Most-cited papers

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
G. von Minckwitz, F. Puglisi, J. Cortés, E. Vrdoljak +12 more
2014The Lancet Oncology136 citations
Semantic Scholar
European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission.
M. Lawler, L. Davies, Simon Oberst, K. Oliver +43 more
2022The Lancet Oncology92 citations Open access
Semantic Scholar
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
T. W. Kim, A. Elme, Z. Kusic, Joonoh Park +12 more
2016British Journal of Cancer69 citations Open access
Semantic Scholar
Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.
E. Vrdoljak, G. Bodoky, J. Jassem, R. Popescu +13 more
2016The Oncologist51 citations Open access
Semantic Scholar
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
T. Tankova, E. Senkus, M. Beloyartseva, S. Borštnar +14 more
2022Cancers49 citations Open access
Semantic Scholar
The European Code of Cancer Practice.
M. Lawler, K. Oliver, S. Gijssels, M. Aapro +20 more
2021Journal of Cancer Policy46 citations Open access
Semantic Scholar
Cancer and coronavirus disease 2019; how do we manage cancer optimally through a public health crisis?
E. Vrdoljak, R. Sullivan, M. Lawler
2020European Journal of Cancer45 citations Open access
Semantic Scholar
Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.
E. Vrdoljak, G. Bodoky, J. Jassem, R. Popescu +12 more
2018The Oncologist32 citations Open access
Semantic Scholar
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.
K. Lindemann, R. D. Christensen, I. Vergote, G. Stuart +11 more
2012Annals of Oncology32 citations Open access
Semantic Scholar
COVID‐19 Pandemic Effects on Breast Cancer Diagnosis in Croatia: A Population‐ and Registry‐Based Study
E. Vrdoljak, M. Balja, Z. Marušić, M. Avirović +8 more
2021The Oncologist24 citations Open access
Semantic Scholar
Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe
E. Vrdoljak, J. Gligorov, Lieve Wierinck, P. Conte +14 more
2020Breast24 citations Open access
Semantic Scholar
Prognostic value of vitamin D receptor and insulin-like growth factor receptor 1 expression in triple-negative breast cancer
Martina Soljic, I. Mrklić, S. Tomić, T. Omrčen +3 more
2017Journal of Clinical Pathology24 citations
Semantic Scholar
Long Follow-up of Patients With Locally Advanced Cervical Cancer Treated With Concomitant Chemobrachyradiotherapy With Cisplatin and Ifosfamide Followed by Consolidation Chemotherapy
Branka Petrić Miše, T. Boraska Jelavić, Ante Strikić, Darijo Hrepić +5 more
2015International Journal of Gynecologic Cancer24 citations Open access
Semantic Scholar
Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer
E. Vrdoljak, T. Omrčen, M. Boban, A. Hrabar
2011Anti-Cancer Drugs24 citations
Semantic Scholar
Adjuvant Chemotherapy in Locally Advanced Cervical Cancer After Treatment with Concomitant Chemoradiotherapy--Room for Improvement?
T. Jelavić, B. Miše, Ante Strikić, M. Ban +1 more
2015Anticancer Research22 citations
Semantic Scholar
Applying Explainable Machine Learning Models for Detection of Breast Cancer Lymph Node Metastasis in Patients Eligible for Neoadjuvant Treatment
J. Vrdoljak, Zvonimir Boban, Domjan Barić, Darko Šegvić +8 more
2023Cancers21 citations Open access
Semantic Scholar
Early HER2-Positive Breast Cancer: Current Treatment and Novel Approaches
M. Ban, Branka Petrić Miše, E. Vrdoljak
2020Breast Care19 citations Open access
Semantic Scholar
Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer
T. W. Kim, A. Elme, Joonoh Park, A. Udrea +9 more
2018Clinical colorectal cancer18 citations Open access
Semantic Scholar
Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.
L. Bošković, M. Gašparić, M. Petkovic, D. Gugić +6 more
2017Breast18 citations Open access
Semantic Scholar
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone
E. Vrdoljak, B. Rini, M. Schmidinger, T. Omrčen +3 more
2013Anti-Cancer Drugs17 citations Open access
Semantic Scholar
Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region
E. Vrdoljak, T. Ciuleanu, G. Kharkevich, J. Mardiak +8 more
2012Expert Opinion on Pharmacotherapy16 citations
Semantic Scholar
Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer
B. Miše, Vesna Dobrić Telesmanić, S. Tomić, Dinka Šundov +2 more
2014Pathology and Oncology Research15 citations
Semantic Scholar
Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer.
M. Ban, B. Miše, Ana Majić, Ivan Dražić +1 more
2018Future Oncology14 citations
Semantic Scholar
Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
D. Miles, C. Zielinski, Miguel Martín, E. Vrdoljak +1 more
2012European Journal of Cancer14 citations Open access
Semantic Scholar
Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy.
J. Bacalja, M. Ulamec, Duje Rako, L. Bošković +3 more
2013In Vivo11 citations
Semantic Scholar
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.
V. Valero, E. Vrdoljak, Bing-He Xu, E. Thomas +10 more
2012Clinical Breast Cancer11 citations
Semantic Scholar
Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients
Dora Čerina, V. Matković, K. Katić, Ingrid Belac Lovasić +7 more
2021Journal of Oncology10 citations Open access
Semantic Scholar
Insights into cancer surveillance in Central and Eastern Europe, Israel and Turkey.
E. Vrdoljak, L. Torday, A. Sella, S. Leyman +6 more
2015European Journal of Cancer Care9 citations Open access
Semantic Scholar
Elevated Tumor Cell-Intrinsic STING Expression in Advanced Laryngeal Cancer
J. Viculin, M. Degoricija, K. Vilović, Ivana Gabela +3 more
2023Cancers8 citations Open access
Semantic Scholar
Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer
Toni Čeprnja, I. Mrklić, Melita Perić Balja, Z. Marušić +7 more
2022Journal of Personalized Medicine8 citations Open access
Semantic Scholar
Is There a Place for Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer?
Dora Čerina, Tihana Boraska Jelavić, Matea Buljubašić Franić, Krešimir Tomić +2 more
2022Current Oncology8 citations Open access
Semantic Scholar
Prognostic significance of MAPK, Topo IIα and E-cadherin immunoexpression in ovarian serous carcinomas.
D. Sundov, B. Miše, I. Mrklic, B. Bačić +2 more
2017Neoplasma (Bratislava)8 citations Open access
Semantic Scholar
Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis.
E. Vrdoljak, M. Gore, S. Leyman, C. Szczylik +7 more
2015Future Oncology8 citations
Semantic Scholar
Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial
E. Vrdoljak, L. Géczi, J. Mardiak, T. Ciuleanu +4 more
2015Pathology and Oncology Research8 citations Open access
Semantic Scholar
The Challenges and Opportunities of the Implementation of Comprehensive Genomic Profiling in Everyday Clinical Practice with Non-Small Cell Lung Cancer: National Results from Croatia
Dora Čerina, K. Krpina, M. Jakopović, Natalija Dedić Plavetić +8 more
2023Cancers6 citations Open access
Semantic Scholar
Chemobrachyradiotherapy and consolidation chemotherapy in treatment of locally advanced cervical cancer
Krešimir Tomić, Gordana Berić Jozić, Anamarija Parić, I. Marijanović +3 more
2021Wiener Klinische Wochenschrift6 citations
Semantic Scholar
AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan).
V. Todorovic, M. Aapro, N. Pavlidis, O. Arsovski +61 more
2019Journal of B.U.ON. : official journal of the Balkan Union of Oncology6 citations
Semantic Scholar
Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel–carboplatin combination therapy in patients with epithelial ovarian cancer?
Tihana Boraska Jelavić, T. Boban, L. Brčić, E. Vrdoljak
2017Anti-Cancer Drugs6 citations
Semantic Scholar
Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer - single institution experience.
M. Ban, J. Viculin, S. Tomić, V. Čapkun +4 more
2016Neoplasma (Bratislava)6 citations Open access
Semantic Scholar
Results of long-term follow-up of patients with superficial bladder carcinoma treated with intravesically applied bacillus Calmette-Guerin vaccine according to the schedule of 6 weekly + 6 monthly instillations.
D. Librenjak, Marijan Šitum, E. Vrdoljak, Kazimir Milostić +1 more
2012Urologic oncology6 citations
Semantic Scholar
Real-world safety and efficacy of nivolumab for ≥ 2nd line treatment of metastatic renal cell carcinoma: A retrospective cohort study in Croatia, Hungary, and Malta.
E. Vrdoljak, C. Magri, M. Gamulin, L. Bošković +4 more
2020Neoplasma (Bratislava)5 citations Open access
Semantic Scholar
Real-World Safety and Efficacy of Nivolumab in Advanced Squamous and Nonsquamous Non-Small-Cell Lung Cancer: A Retrospective Cohort Study in Croatia, Hungary, and Malta
E. Vrdoljak, M. Jakopović, L. Géczi, K. Bogos +5 more
2020Journal of Oncology5 citations Open access
Semantic Scholar
Abstract P3-06-08: Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC)
J. Cortés, E. Vrdoljak, F. Puglisi, N. Marschner +12 more
20155 citations
Semantic Scholar
Abstract PD2-4: Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
F. Puglisi, J. Cortés, E. Vrdoljak, J. Gligorov +11 more
20155 citations
Semantic Scholar
Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia
Dora Čerina, V. Matković, K. Katić, Ingrid Belac Lovasić +4 more
2022Journal of Personalized Medicine4 citations Open access
Semantic Scholar
Predictors of outcome in elderly patients with metastatic colorectal cancer: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment
T. Omrčen, A. Katić, S. Tomić, D. Eterović +1 more
2020Anti-Cancer Drugs4 citations
Semantic Scholar
An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) + best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.
T. W. Kim, A. Elme, Z. Kusic, Joonoh Park +12 more
20164 citations
Semantic Scholar
Combination of adjuvant radiotherapy and androgen deprivation therapy after radical prostatectomy in high risk prostate cancer patients - results from retrospective analysis.
T. Omrčen, D. Hrepić, Tihana Boraska Jelavic, E. Vrdoljak
2015Journal of B.U.ON. : official journal of the Balkan Union of Oncology4 citations
Semantic Scholar
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
L. Vahdat, E. Vrdoljak, H. Gómez, Ru-Bi K. Li +5 more
2013Journal of Geriatric Oncology4 citations Open access
Semantic Scholar
Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer
E. Vrdoljak, M. Šekerija, S. Pleština, Ingrid Belac Lovasic +4 more
2021European Journal of Health Economics3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Tomić×10
Invite
S. Tomić — researcher profile on SciRah
Ž. Bajić×8
Invite
Ž. Bajić — researcher profile on SciRah
B. Miše×7
Invite
B. Miše — researcher profile on SciRah
T. Omrčen×6
Invite
T. Omrčen — researcher profile on SciRah

×5

Invite

J. Gligorov — researcher profile on SciRah

Dora Čerina×5

Invite

Dora Čerina — researcher profile on SciRah

Invite

L. Torday — researcher profile on SciRah

C. Zielinski×4

Invite

C. Zielinski — researcher profile on SciRah

Invite

J. Jassem — researcher profile on SciRah

Invite

J. Mardiak — researcher profile on SciRah

L. Bošković×4

Invite

L. Bošković — researcher profile on SciRah

Invite

C. Szczylik — researcher profile on SciRah